ECM
NAMS icon

ExodusPoint Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

ExodusPoint Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,644
Closed -$1.22M – 1799
2025
Q1 		$1.22M Buy
+59,644
New +$1.33M 0.01% 867

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ExodusPoint Capital Management's NAMS Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 59,644 shares — an estimated $1.22M sold.

ExodusPoint Capital Management first reported a position in NAMS in Q1 2025 and held it in 1 quarter. The position peaked at $1.22M in Q1 2025. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

  • ExodusPoint Capital Management reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 59,644 NewAmsterdam Pharma shares in Q2 2025, an estimated $1.22M.
  • ExodusPoint Capital Management first reported a position in NewAmsterdam Pharma in Q1 2025 and held it in 1 quarter.
  • ExodusPoint Capital Management's NewAmsterdam Pharma position peaked at $1.22M in Q1 2025.
  • 131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.